Alzheimers brain decline slashed in half by thrilling new twice-a-year drug: trial

Is a major medical breakthrough on the horizon?A new drug may prove to be a game changer in Alzheimer’s research following the results of an incredible trial.Patients administered low-dose diranersen injections showed 54% less decline on a test of memory and thinking over nearly two years, suggesting the experimental treatment could slow the deadly disease more effectively than any therapy developed to date, per the Telegraph.AdvertisementIt is also the first drug to show a decline in tau, a protein that forms harmful tangles linked to brain cell death.

The diranersen injections use gene-silencing technology to confront Alzheimer’s at its source, blocking the RNA messages that signal for brain cells to produce tau.Biogen announced the exciting results on Tuesday, Nov.17, following the Clinical Trials on Alzheimer’s Disease 2026 conference.Advertisement“The two-year data presented at CTAD mark an important milestone for diranersen, demonstrating not only sustained clinical benefit but also an increasing magnitude of effect at two years,” said Priya Singhal, executive vice president and head of development at Biogen.

“These findings strengthen the growing body of evidence supporting tau as a therapeutic target and underscore the potential of diranersen to meaningfully impact disease progression for people living with early Alzheimer’s disease,” she continued.Professor Reisa Sperling, a co-author of the study and a professor of neurology at Harvard Medical School, who presented the brain scan findings, spoke with the Telegraph, describing the results as “thrilling.”Advertisement“These data suggest that we’re not just slowing the accumulation of tau, but we are lowering aggregated tau from baseline,” she said.“We reversed Alzheimer pathology.

We removed tau tangles.That’s a remarkable statement,” Professor Jeffrey Cummings, also a co-author of the study, told the Clinical Trials on Alzheimer’s Disease conference in Boston, according...

Read More 
PaprClips
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by PaprClips.
Publisher: New York Post

Recent Articles